Allspring Global Investments Holdings LLC Acquires Shares of 2,871,561 Elanco Animal Health Incorporated $ELAN

Allspring Global Investments Holdings LLC acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,871,561 shares of the company’s stock, valued at approximately $66,390,000.

A number of other large investors also recently bought and sold shares of the company. UBS Group AG boosted its holdings in shares of Elanco Animal Health by 56.7% in the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after acquiring an additional 5,961,457 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Elanco Animal Health by 11.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after buying an additional 3,717,404 shares in the last quarter. Invesco Ltd. raised its stake in shares of Elanco Animal Health by 336.0% during the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after buying an additional 3,690,735 shares in the last quarter. Artemis Investment Management LLP acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $55,693,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Citigroup boosted their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Finally, TD Cowen raised their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $28.55.

Insider Buying and Selling at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction on Friday, May 15th. The stock was bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $25.84 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The firm has a market capitalization of $12.91 billion, a price-to-earnings ratio of -51.68, a price-to-earnings-growth ratio of 1.70 and a beta of 1.68. Elanco Animal Health Incorporated has a one year low of $13.39 and a one year high of $27.72. The company has a 50 day moving average price of $23.63 and a 200 day moving average price of $23.89.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the business earned $0.37 EPS. Elanco Animal Health’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.